Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator)
Neurological adverse effects · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: neurological side effects compared with other antibody (stratified by comparator) (low certainty).
1 finding from 1 review
- Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes onlyRR 13.1 [1.43, 120.05]2 studies · 132 participantsLow